SELLAS Life Sciences to be Added to Russell 3000® and Russell 2000® Indexes

NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the Company will be added to the Russell 3000^® and Russell 2000^® Indexes, effective after the U.S. market close on June 27, as part of the 2025 Russell indexes annual reconstitution.

Read more at globenewswire.com